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Infantile hemangioma (IH), which is the most common tumor in infants, is a benign vascular neoplasm resulting
from the abnormal proliferation of endothelial cells and pericytes. For nearly a century, researchers have noted that
IH exhibits diverse and often dramatic clinical behaviors. On the one hand, most lesions pose no threat or potential
for complication and resolve spontaneously without concern in most children with IH. On the other hand,
approximately 10% of IHs are destructive, disfiguring and even vision- or life-threatening. Recent studies have
provided some insight into the pathogenesis of these vascular tumors, leading to a better understanding of the
biological features of IH and, in particular, indicating that during hemangioma neovascularization, two main
pathogenic mechanisms prevail, angiogenesis and vasculogenesis. Both mechanisms have been linked to alterations
in several important cellular signaling pathways. These pathways are of interest from a therapeutic perspective
because targeting them may help to reverse, delay or prevent hemangioma neovascularization. In this review, we
explore some of the major pathways implicated in IH, including the VEGF/VEGFR, Notch, β-adrenergic, Tie2/angiopoietins,
PI3K/AKT/mTOR, HIF-α-mediated and PDGF/PDGF-R-β pathways. We focus on the role of these pathways in the
pathogenesis of IH, how they are altered and the consequences of these abnormalities. In addition, we review the
latest preclinical and clinical data on the rationally designed targeted agents that are now being directed against
some of these pathways.
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Infantile hemangioma (IH) is a common disorder in in-
fancy, with an estimated prevalence of 5 to 10%. If left
untreated, these tumors are characterized by a rapid
growth phase during the first year of life, followed by
slow involution, which may continue until the age of
10–12 years (Figure 1) [1,2]. However, some IHs will
leave residual changes, such as telangiectasias, fibro-fatty
tissue, scars, excessive atrophic skin and pigment
changes. In 10% of cases, IHs grow dramatically and des-
troy tissue, impair function or even threaten life [3]. The
standard treatment options for IH include corticoste-
roids or surgical excision, and the options in life- or
sight-threatening cases include treatment with vincris-
tine, interferon or cyclophosphamide. Unfortunately,* Correspondence: jijiyuanyuan@163.com; bboxiang@163.com
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stated.none of these therapeutic modalities are ideal due to re-
strictions or potential serious side effects [4-7]. β-
blockers have recently been introduced as a safe and ef-
fective treatment for IH [8-11]. However, their use is not
without risk, and not all tumors respond to these drugs
[12,13]. These issues have spurred extensive research to
clarify the signaling pathways implicated in hemangioma
neovascularization in the hope that a greater under-
standing of its molecular pathogenesis will reveal new
strategies to tackle IH.
The initial histochemical work of Mulliken and Glowacki
[14], examining endothelial cell (EC) morphology, shed
light on the cellular components of IH. In the past decade,
hemangioma-derived progenitor/stem cells (HemSCs), mes-
enchymal stem cells (Hem-MSCs), endothelial progenitor
cells (HemEPCs), ECs (HemECs) and perivascular cells
(Hem-pericytes), all of which comprise the IH, have been
isolated (Table 1) [15-18]. In general, CD133 was used as
a stem cell biomarker for the isolation of HemSCs from
IH tissues. HemEPCs were purified from HemSCs basedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Hematoxylin and eosin (H&E) stained sections of proliferating, involuting and involuted phases of IH. The proliferating phase is
characterized by densely packed tumor cells that form immature vessels (A). In the involuting phase, disorganized vasculature consists of flat
endothelium and pericytes (B). The tumor is replaced by fat and/or connective tissues in the involuted phase (C). Scale bar = 100 μm.
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MSCs didn’t express CD31 or CD34. In IH tissues, CD133
expression was found to be located in both perivascular
region and endothelium [19]. Therefore, HemSCs may
contain both of Hem-MSCs and HemEPCs. Studies from
different groups have demonstrated that HemSCs have
the ability to self-renew and can differentiate into endo-
thelium, adipocytes and pericytes in vitro [15,20]. When
implanted subcutaneously into nude mice, HemSCs can
produce human glucose transporter-1 (GLUT-1) positive
microvessels at 7–14 days [15,20-22].
We now recognize that IH may be not only a disorder
of angiogenesis (i.e., the sprouting of new vessels from
existing ones) but also – at least in part – a disorder of
vasculogenesis (i.e., the de novo formation of new blood
vessels from stem cells) [20,24,25]. Improved knowledge
of the signaling pathways that regulate angiogenesis and
vasculogenesis has led to the identification of several pos-
sible therapeutic targets that have driven the developmentTable 1 Cellular components isolated from IH
Cell type Abbreviation Cell marker
Hemangioma-derived endothelial cell HemEC CD31/PECAM-1, vWF
VEGFR-2, Tie-2 and V
Hemangioma-derived endothelial
progenitor cell




Hem-MSC SH2(CD105), SH3, SH
CD29, α-SMA and C
Hemangioma-derived stem cell HemSC CD90, CD133, VEGFR
neuroplin-1 and CD




*CD133, a pentaspan membrane protein, is used as a stem cell biomarker for the is
for self-renewal, tumorigenesis, metabolism, differentiation, autophagy, apoptosis a
the development of IH.of molecularly targeted therapies. Because many of the
signaling pathways are implicated in the pathogenesis of
various tumor types, insight gained from these studies will
enable the development of target-specific drugs, not only
for IH but also for malignant vascular tumors. This review
will highlight the most important of these findings. Al-
though the signaling pathways involved in the develop-
ment of IH are described separately below, there are
numerous interactions among them, indirectly reflecting
the complexity of IH pathogenesis.
VEGF/VEGFR pathway
The human vascular endothelial growth factor (VEGF)
family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D
and placental growth factor (PIGF). These growth fac-
tors play pivotal roles in embryonic development and
angiogenesis-dependent disease [26]. Many reports have
confirmed that excessive VEGF expression in IH tissue
parallels the proliferating phase of its growth. Conversely,Characteristics
, E-selectin,
E-cadherin
Immature endothelial cells; Clonal expansion;
Increased proliferation, migration, tumor
formation and survival ability.
34, CD31,
and vWF
Immature endothelial cells; Increased adhesion,
migration and proliferation in the presence




osteoblastic and myoblastic differentiation
-1, VEGFR-2,
146
Multilineage differentiation: ECs, neuronal cells,
adipocytes, osteocytes and chondrocytes;





y chain and CD90
Increased proliferation ability; Reduced contractility;
Diminished ability to stabilize blood vessels in IH.
olation of progenitor/stem-like cells from IH tissues. CD133 is also responsible
nd regeneration [23]. However, little is known about its biological functions in
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creases, and many angiogenesis inhibitors become prom-
inent [21,27,28].
The functions of the different VEGF family members
are determined by their receptor specificity. Two recep-
tors for VEGF are members of the tyrosine-kinase family
and conserved in ECs. These VEGF receptors (VEGFR)
are VEGFR-Flt-1 (VEGFR-1) and VEGFR-Flk-1/KDR
(VEGFR-2). VEGFR-1 and VEGFR-2 are located on ECs,
bone-marrow derived hematopoietic cells and tumor cells,
etc. [26,29]. The expression of these receptors is low in
normal tissues and only upregulated during the develop-
ment of those pathological states when neovascularization
occurs [30]. Another receptor, VEGFR-3, is primarily
expressed in lymph nodes and tumor blood vessels
[31,32]. Neuropilin-1 and neuropilin-2 were discovered as
coreceptors that that enhanced the binding and effective-
ness of the VEGF stimulation of their receptors [33].
Upregulated autocrine VEGF-A/VEGFR-2 loop in HemEC
One of the most intensely studied factors involved in
angiogenesis and vasculogenesis is VEGF-A. VEGFR-2
is known to mediate the majority of the downstreamFigure 2 The VEGF signaling pathway in HemECs and HemSCs. Upon lig
different tyrosine residues. Phosphorylation in turn elicits differential downstreangiogenic effects of VEGF-A, including microvascular
permeability, EC proliferation, migration and survival
[34]. Upon the activation of VEGFR-2 in ECs, three
major secondary messenger pathways trigger multiple
downstream signals that promote angiogenesis. These
pathways are the following: the mitogen-activated pro-
tein/ERK kinase (MEK)/extracellular signal-regulated
kinase (ERK) cascade, the phosphatidylinostitol-3 kinase
(PI3K)/serine-threonine protein kinase/Akt cascade and
the phospholipase C-γ/intracellular Ca2+/(protein kinase
C (PKC) cascade [35,36]. The genetic deletion of VEGF-A
or its primary signaling receptor VEGFR-2 results in early
embryonic lethality, associated with a near-complete block
of hematopoietic and vascular development [37].
High-VEGFR-2 cells are well documented to exhibit a
higher capacity of self-renewal and superior growth
in vitro and in vivo compared with a low-VEGFR-2 cell
population [33,38]. HemECs demonstrate the phenotype
of a constitutively active autocrine VEGF-A/VEGFR-2
loop (Figure 2), which renders the cells more sensitive to
paracrine/external stimulation by VEGF-A and results in
the increased proliferation and migration of cells and
tumor formation [39,40]. These characteristics likely resultand binding, VEGF receptors dimerize, leading to the phosphorylation of
am signaling events.
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sense mutations in the kinase insert of the VEGFR-2 gene
have been found in IHs [41]. In addition, imbalances in
gene expression have been reported in mesenchymal com-
partments compared to normal tissues, suggesting a pos-
sible reciprocal interaction between HemECs and the
surrounding cells [42-44]. Alternatively, HemECs may ori-
ginate from progenitor/stem-like cells, which are known
to display robust proliferative and clonogenic capabilities
and to express high levels of VEGF-A [15,21]. The expres-
sion level of VEGF is also increased in HemECs, although
this increase is not dramatic [40]. Finally, COSMC was re-
ported to be overexpressed in proliferating IHs, with an
association with the enhanced VEGF-mediated phosphor-
ylation of VEGFR-2 and its downstream signaling [45].
The abnormal activation of VEGFR-2 on the cell sur-
face may also be beneficial to the survival of HemECs as
VEGF-A plays a critical role in protecting ECs against
apoptotic cell death [46,47]. In addition, this inhibition
of EC apoptosis can improve angiogenesis and vasculo-
genesis in patients with ischemia [30]. We recently indi-
cated that maintaining Bcl-2 expression via VEGF-A/
VEGFR-2 signaling in primary HemECs blocked the cells
from apoptotic death in the absence of external VEGF-
A. Moreover, the inactivation of PI3K/Akt suppressed
the VEGF-A/VEGFR-2-mediated anti-apoptotic effect
and unleashed the inhibitory effect of VEGF-A/VEGFR-
2 signaling over the reduction of Bcl-2 expression,
thereby amplifying the activation of the caspase cascade
[48]. These findings suggest that HemECs may be able
to adapt to the abnormal physical environment of the
tumor by undergoing a form of reprogramming that in-
volves an increase in apoptosis resistance and by up-
regulating a VEGF autocrine survival feedback loop to
sustain these effects and stabilize the aberrant phenotype.Figure 3 Double immunofluorescence staining of IH tissues. (A), Prolif
(red), smooth muscle marker α-SMA (green) and nuclei (blue) (laser fluores
stained for CD31 (red), VEGF-A (green) and nuclei (blue) (fluorescent microMoreover, recent research efforts revealed that pericytes,
in addition to producing VEGF-A that acts in a paracrine
fashion (Figure 3), can stimulate the autocrine expression
of VEGF-A by tumor ECs, both of which could lead to a
general suppression of EC apoptosis [49]. Interestingly,
HemSCs and Hem-pericytes also secrete high levels of the
angiogenic VEGF-A [21,42]. Thus, various combinations
of strategies, including the development of novel potent
tyrosine kinase inhibitors against VEGFR-2 and potential
to abrogate its downstream pathways, can be investigated
to achieve synergistic effects on HemEC apoptosis and
therefore on hemangioma regression.
Discrepancy of VEGFR-1 signaling in HemSCs and HemECs
In contrast to other VEGFR genes, VEGFR-1 expresses
two types of mRNA, one for a full-length receptor and
another for a soluble short protein known as soluble
VEGFR-1 (sFlt-1). The binding-affinity of VEGFR-1 for
VEGF-A is one order of magnitude higher than that of
VEGFR-2, whereas the kinase activity of VEGFR-1 is
about ten-fold weaker than that of VEGFR-2. Therefore,
VEGFR-1 is considered a negative regulator of angiogen-
esis and vasculogenesis during development [50]. VEGFR-
1−/− mice show an overabundance of blood vessels and
overgrowth of immature ECs, similarly to those features
observed in IH [51].
A reduction of VEGFR-1 expression has been implicated
in the proliferation of infantile HemECs and tissue
[40,52]. The mechanism for this low expression in
HemECs was shown to be the sequestration of β1-inergrin
in a multiprotein complex composed of tumor endothelial
marker-8 (TEM8) and VEGFR-2, which inhibits nuclear
factor in activated T cells (NFAT)-mediated VEGFR-1
transcription [40]. However, VEGFR-1 is relatively over-
expressed in HemSCs [53]. The involvement of VEGFR-1erating phase IH tumor section stained for endothelial maker CD31
cent confocal microscopy). (B), Proliferating phase IH tumor section
scopy). The nuclei are stained with DAPI. Scale bars are 100 μm.
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mechanism: the activation of HemSC function, with a
subsequent increase in vasculogenesis. VEGF-A, either en-
dogenous or exogenous, significantly induces VEGFR-1-
mediated ERK1/2 phosphorylation in HemSCs and
promotes the differentiation of HemSCs to HemECs
(Figure 2). Moreover, VEGF-B, which is the specific ligand
for VEGFR-1, is highly expressed in HemECs and induces
similar effects [53]. These results clearly indicate that not
only the paracrine function of VEGF-B from HemECs but
also the persistent autocrine signaling through the VEGF-
A/VEGFR-1 loop in HemSCs contributes to enhanced IH
vasculogenesis in general.
Notch pathway
The Notch pathway is a conserved ligand-receptor sig-
naling mechanism that modulates cell fate and differen-
tiation. The interaction of Notch receptors (Notch 1 to
4) with their ligands (Delta-like 1, -3, -4, Jagged-1 and −2)
leads to the cleavage of the transmembrane Notch recep-
tor, giving rise to the Notch intracellular domain (NICD)
that migrates into the nucleus. In the nucleus, the NICD
associates with a transcription factor, recombination signal
binding protein for immunoglobulin kappa J (RBP-Jk),
and activates transcription from the RBP-Jk DNA binding
site. The NICD-RBP-Jk complex upregulates the expres-
sion of primary target genes of Notch signaling, such as
hairy and enhancer of split (HES) and HES-related protein
(HERP/HEY) family of transcription factors [54,55].
Notch expression in IH
Although the expression levels of the Notch components
are likely dynamic during development, making transient
expression difficult to detect, current data suggest that
many known Notch components, mainly two ligands
(Delta-like-4 and Jagged-1), three receptors (North-1, -3
and −4) and four effectors (HES-1, HEY1, HEY2 and
HEYL) are involved in the pathogenesis of IH. Both
Jagged-1 and Notch-4 are increased in proliferating IHs.
All transcript levels of Notch-1, Notch-3, Notch-4,
Jagged-1 and Delta-like-4 (Dll4) were higher in the IH
than in the placenta (a commonly used tissue for com-
parisons). Conversely, Notch-2 is strongly decreased in
both proliferating and involuting IHs [44,56].
Notch signaling triggers cell-cell interactions in IH
Notch signaling is initiated when the extracellular do-
main of the receptor engages ligands found on neighbor-
ing cells that are in close proximity to one another. Thus,
Notch signaling depends on cell-contact-dependent inter-
actions. In many cases, the cell that presents the ligand is
a cell that does not have Notch signaling present, thus dis-
tinguishing two neighboring cells into one with ligand
with little Notch signaling and one with receptor and highNotch signaling [57]. In a study by Wu et al. [44], the in-
vestigators demonstrated that HemSCs have distinct
Notch expression patterns from HemECs. In HemSCs,
where Notch3 is strongly expressed, HES1, HEY1, and
HEYL were expressed at levels 10 to 100 times to that of
HEY-2. In HemECs, however, Notch-1, Notch-4 and
Jagged-1 have higher expression levels. HEY-2 proteins
were often found to be expressed in HemECs. However,
HEY-2 was not uniformly present in all ECs, suggesting
that only a subset of IH ECs express the Notch target [56].
These data suggest the possibility that the Notch pathway
might also contribute to establishing two distinct subpop-
ulations at different steps of angiogenesis in IH, such as
ECs versus smooth muscle cells (SMCs)/pericytes, arteries
versus veins and large vessels versus capillaries [54,58,59].
We highlight the concept that ligand-receptor interactions
in Notch signaling depend on contact between two cells,
which may be two different cell types. Notch ligands in-
volved in IH angiogenesis may be presented by HemECs,
pericytes or HemSCs. Interestingly, research by Boscolol
et al. [43] revealed that endothelial-derived Jagged-1 can
induce HemSCs to acquire a pericyte-like phenotype,
which is a crucial step in the vasculogenesis of IH. Disrup-
tion of the juxtacrine interaction between endothelial
Jagged-1 and Notch receptors on HemSCs inhibited blood
vessel formation in IH murine models. However, mice
homozygous for a null mutation of several components of
the Notch pathway, including Notch-1 and Jagged-1, re-
sulted in embryonic lethality with vascular remodeling
defects. Vasculogenesis proceeded normally in these mu-
tants, whereas the next step, angiogenesis, was disrupted
[60,61]. These data suggest that the upregulated Jagged-1
expression in the IH endothelium may provide a unique
effect to control the vascular development of IH.
Is there a specific relationship between VEGF and Notch
pathways in IH?
In vivo and in vitro studies have revealed several ways in
which the VEGF and Notch pathways interact. Particu-
larly, VEGF increases Dll4 expression [62,63]. Dll4 is
strongly expressed by the ECs of sprouting angiogenic
vessels, which commonly respond to VEGF signals. There
is evidence that the blockade of VEGF in tumors results in
a rapid decrease of Dll4 expression in tumor ECs [64].
Interestingly, although HemECs had higher VEGF-A
levels and increased activation of VEGFR-2 compared
with normal ECs [40], the Dll4 levels in HemECs were
lower than those found in normal ECs [44]. These data
argue against the idea that VEGF interacts with Notch
signaling in IH. However, several lines of evidence indicate
otherwise. For example, the disruption of Dll4 or
endothelium-specific loss of Notch1 increases the superfi-
cial plexus vascular density and causes an excess of angio-
genic sprouts. This loss of Notch signaling is associated
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have suggested that reduced Notch activity resulted in re-
duced VEGFR-1 expression and increased VEGFR-2 ex-
pression in cultured ECs [65,66]. In addition, Hellstrom
et al. [67] demonstrated that Dll4-Notch signaling within
the endothelial cell population serves to suppress the
tip-cell phenotype. The retinal vascular abnormalities in
Dll4+/− mice and after long-term treatment with γ-
secretase inhibitors might also result from changes in the
pattern of VEGF-A expression [67]. In contrast to Dll4,
Jagged-1 is proangiogenic protein that functions by down-
regulating Dll4-Notch signaling. Jagged-1 also counteracts
Dll4-Notch signaling interactions between stalk ECs,
which helps to sustain elevated VEGF receptor expression
in the newly formed and therefore immature vascular
plexus at the angiogenic front [68]. By analogy to studies
of VEGF signaling in HemECs, Notch components may
be novel regulators for VEGF signaling in IH (Figure 4).Figure 4 Tip/stalk cell specification during spouting angiogenesis and
formed vessels in response to pro-angiogenic cues, such as hypoxia-induce
Dll4 on endothelial cells, which in turn activates Notch receptors on adjace
signaling, providing an additional feedback loop between the two pathwa
expression of VEGFR-1 and VEGFR-3 in those cells. In contrast, Notch activa
concomitant decrease in the proangiogenic response to exogenous VEGF. Bo
response in connector cells that exhibit Notch activation.Until now, the involvement of Notch in IH develop-
ment has remained poorly understood, and many issues
still need to be addressed. How does the Notch pathway
play a role in the interaction between HemECs and
SMCs/pericytes? How are the different roles that the
Notch pathway plays, such as arteriovenous patterning,
tip cell differentiation and vessel wall formation, inte-
grated during vascular development in IH? How do
some of the key downstream Notch target genes affect
IH vessels in the presence of high VEGF levels? And fi-
nally, does the expression and/or activity of VEGF com-
ponents in IH depend on the nature of Notch signaling
or vice versa? These questions should be addressed by
future research efforts.
β-adrenergic signaling
The β-adrenergic receptors (β-ARs), a family of G-protein-
coupled receptors that are activated by β-adrenergicvascular development. Angiogenic sprouts emerge from the newly
d VEGF. VEGF stimulus, acting via VEGFR-2, increases the expression of
nt endothelial cells. Furthermore, VEGFRs are regulated by Notch
ys: activated Notch receptors on ECs can positively regulate the
tion leads to the reduction of VEGFR-2 expression in cell culture and a
th of these effects would likely lead to a lower migratory or proliferative
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a series of signaling cascades, thereby leading to multiple,
cell-specific responses (Figure 5). The ligation of β-ARs by
β-adrenergic agonists triggers a G-protein coupled signal-
ing cascade that stimulates cyclic AMP (cAMP) synthesis.
This secondary messenger, cAMP, regulates many cellular
functions through its effectors, such as cAMP-dependent
protein kinase (PKA) and EPAC (exchange proteins dir-
ectly activated by cAMP) [69-71]. Preclinical studies haveFigure 5 β-adrenergic signaling modulates multiple cellular processe
epinephrine or norepinephrine triggers a G-protein coupled signaling cascad
can mediate multiple signal pathways via the phosphorylation of various dow
of EPAC leads to the Rap1A-mediated activation of Raf/MAPK signaling pathwdemonstrated that β-adrenergic signaling can regulate
multiple fundamental biological processes underlying the
progression and metastasis of tumors, including the
promotion of inflammation [72-74], angiogenesis [75-78],
migration [79], invasion [80,81] and resistance to pro-
grammed cell death [82-85]. Some evidence suggests that
the stimulation of β-adrenergic signaling can also inhibit
DNA damage repair and the cellular immune response
[86,87] and promote surgery-induced metastasis [88,89].s in tumor progression and metastasis. The ligation of β-ARs by
e that stimulates cAMP synthesis. cAMP activates the PKA protein, which
nstream signal proteins. In another major pathway, the cAMP activation
ays and downstream effects on diverse cellular processes.
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prescribed β-blockers may favorably impact cancer pro-
gression and metastasis in patients [90].
In the six years since June 2008 when Leaute-Labreze
et al. [11] first described their serendipitous observation
of the anti-proliferative effect of propranolol on severe
IHs, many articles regarding β-blocker therapy for IHs
have been published [8,10,91]. However, despite the ap-
parent widespread use of β-blockers, their mechanism of
action in IHs has not yet been elucidated. Agonists and
antagonists of β-ARs are known to act antithetically via
the same intracellular pathways [92]. Given that the ex-
pression of all three β-ARs has been demonstrated in IH
tumors [93-96], does β-adrenergic signaling play a role
in the pathogenesis of IH? This hypothesis was immedi-
ately and, to some degree, indirectly testable by Mayer
et al. [97], who found that intrauterine exposure to β2-
sympathomimetic hexoprenaline can increase the oc-
currence of IH in preterm infants, suggesting a role for
β-AR stimulation in the initiation of IH. Furthermore,
we recently demonstrated that the activation of β-ARs
resulted in increased HemEC proliferation and upregula-
tion of the ERK signaling cascade. VEGFR-2-mediated
ERK signaling was also upregulated upon β-AR activa-
tion to mediate the proliferation of HemECs [96]. These
findings unveil a functional connection between the β-
ARs and IH development. However, confirmatory studies
in animal models of IH and mechanistic studies are
needed to clearly define the role of β-adrenergic signal-
ing in the growth and involution of IH [98].
Tie-2/Angiopoietin signaling
Tie-2 and the angiopoietins (Ang), another receptor-
ligand system involved in physiological and pathogenic
angiogenesis, have also been reported to be associated
with the development of IHs. Tie-2 tyrosine kinase re-
ceptor is expressed specifically on vascular ECs and on a
certain subtype of macrophages implicated in angiogen-
esis. Ang-1 and Ang-2 have been identified as bona fide
ligands of the Tie-2 receptor. Ang-1, which is mainly
expressed by pericytes, is a critical player in vessel mat-
uration and mediates the migration, adhesion and sur-
vival of ECs. Only tetrameric or higher multimeric forms
of Ang-1 activate Tie-2, whereas oligomeric Ang-2 is a
weak context-dependent agonist of Tie-2 and may even
antagonize the receptor [99]. Ang-1-mediated Tie-2 acti-
vation stimulates a number of intracellular signaling
pathways, such as the PI3K/Akt pathway, which pro-
motes EC survival and nitric oxide (NO) synthesis by
the activation of the mitogen-activated protein kinase
(MAPK) pathway [100,101]. The deletion of Ang-1 be-
tween E10.5 and E12.5 results in an enlargement of
vessel diameter, mainly in the capillaries [102,103]. Its
phenotypes were comparable with those of IH, i.e.,increased numbers of EC and overly covered by peri-
cytes [25].
Using laser capture microdissection, Calicchio et al.
[52] found Ang-2 was significantly increased in the IH
endothelium compared with the placental vessels. In
contrast, Ang-1 was decreased in proliferating IH rela-
tive to the placenta. Yu et al. [104] demonstrated that
Tie-2 was specifically increased in HemECs and that this
increase corresponds to enhanced cellular responses to
the Tie-2 agonist Ang-1. Consistent with these findings,
Boscolo et al. [42] revealed that hemangioma-derived
pericytes exhibited low levels of Ang-1, resulting in a di-
minished ability to stabilize blood vessels in IH.
HIF-α-mediated pathway
Hypoxia is one of the most powerful inducers of angio-
genesis and vasculogenesis. During tumorigenesis, when
tumor cells outgrow the limiting diffusion distance to
nearby blood vessels and become hypoxic, the balance
between pro-angiogenic and anti-angiogenic molecules
is tipped towards pro-angiogenic molecules. This angio-
genic switch provokes the expression of a variety of angio-
genic factors by tumor cells and stromal cells, including
VEGF-A, stromal cell-derived factor-1α (SDF-1α), fibro-
blast growth factor (FGF), platelet-derived growth factors
(PDGFs), lysophosphatidic acid (LPA) and Ang [105].
Although the initiating mechanism during the patho-
genesis of IH has yet to be discovered, there is evidence
that tissue hypoxia may contribute to their explosive
growth. The initial clinical description of the promon-
tory mark of IH as an ‘area of low blood flow’ suggests
that tissue ischemia, a powerful stimulus for neovascu-
larization, may be involved [106]. The hypothesis that is-
chemia/hypoxia plays a crucial role is also supported by
the clinical observation of a blanched area of skin in the
position of the future hemangioma. This region may be
an area of local ischemia in the skin, caused by some un-
known events, that creates a hypoxic environment and
thus triggers growth factor expression.
In keeping with the observations described above, Ritter
et al. [107] proposed a mechanism for myeloid cell-
facilitated IH growth involving the hypoxia-induced ex-
pression of several growth factors (e.g., insulin-like growth
factor-2) that drive endothelial proliferation. Kleinman
et al. [108] demonstrated the presence of hypoxia-induced
mediators of progenitor/stem cell trafficking in proliferat-
ing IH specimens and revealed that the combination of
hypoxia and estradiol results in a synergistic effect on the
upregulation of matrix metalloproteinase (MMP-9) in ECs
in vitro, a key factor in endothelial progenitor cells (EPCs).
The transcription factor hypoxia inducible factor (HIF-1α)
was also stabilized in proliferating hemangioma speci-
mens. Subsequent investigations revealed that HemECs
show significantly a higher expression of HIF-1α than
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tor to the elevated VEGF levels produced in HemECs, and
the decreased expression of HIF-α reduces the prolifera-
tion of these cells [39]. Moreover, the benefit observed
during IH treatment by propranolol has been suggested to
also be primarily due to the reduction of HIF-1α expres-
sion [109]. This suggestion has been confirmed by Chim
et al. [110], who demonstrated that propranolol exerts its
suppressive effects on HemECs through the HIF-1α-
VEGF-A angiogenesis axis, the effects of which were me-
diated through the PI3/Akt and p38/MAPK pathways.
Altogether, these findings indicate a direct and causative
association between HIF-α signaling and the development
of IH.
An additional possible effect of HIF-1α signaling in the
pathogenesis of IH is mediation of EC autophagy. In their
recent study, Chen et al. [111] revealed that a short expos-
ure to hypoxia can induce HIF-α/BNIP3-dependent au-
tophagy, which may promote EC survival growth. In
contrast, if the hypoxia stress is prolonged, the autophagy
activation may in turn become 5′-AMP-activated protein
kinase (AMPK)/mammalian target of rapamin (mTOR)
dependent and therefore cause programmed EC death.
However, the evidence from this study was weakened by
not being performed in IH-derived cells or in IH animal
models.
PI3K/Akt/mTOR signaling
PI3K generates 3-phosphorylated inositol lipids, causing
the activation of downstream signaling, resulting in the
activation of protein kinase B (PKB; also called c-Akt),
which regulates, among others, mTOR, glycogen syn-
thase kinase-3β and Forkhead box O transcription factor
activity. Downstream targets of mTOR include p70 ribo-
somal protein 6S kinase (S6K). The overactivation of the
PI3K/Akt/mTOR pathway, a signaling pathway that
plays a key role in cellular growth and survival, has been
implicated in various tumor pathogeneses, and as such,
the inhibition of the PI3K/Akt/mTOR pathway is of
therapeutic interest [112-114]. Medici and Olsen [39]
found that HemECs had constitutively active PI3K/Akt/
mTOR/p70S6K and tested their hypothesis that these
cells could be sensitive to mTOR inhibitors (e.g., rapa-
mycin). Finally, they demonstrated that the treatment of
HemECs with rapamycin results in a significant decrease
in HIF-1 and VEGF-A levels and in reduced prolifera-
tion. Strikingly, in vivo and in vitro studies further dem-
onstrated that rapamycin can reduce the self-renewal
capacity of the HemSCs, diminish the differentiation po-
tential and inhibit the vasculogenic activity of these cells
in vivo [115]. These preclinical data provide us with a
pharmacological basis for the potential use of rapamycin
in β-blocker-resistant IHs. Nonetheless, the mechanism
that accounts for the effects of rapamycin in IH is farfrom clear, and a growing list of side effects make it
doubtful that rapamycin would ultimately be beneficial
in pediatric patients [112].
PDGF-B/PDGFR-β signaling
The first evidence for a possible regulatory role of PDGF-
B/PDGF receptor-β (PDGFR-β) signaling in IHs was pro-
vided by Walter et al. [116]. These researchers established
a genetic linkage with chromosome 5q in three familial
hemangiomas. The region, 5q31-33, contains three candi-
date genes involved in blood vessel growth. These genes
were fibroblast growth factor receptor-4 (FGFR4), PDGFR-
β and VEGFR-3 [116]. Subsequently, a study examining
global gene expression changes between the IH growth
phases by the genome-wide transcriptional profiling of
blood vessels showed a reduction in PDGFR-β expression
during the involutive phase [52]. These findings provide
the possibility that PDGF-B/PDGFR-β signaling may play
a role in IH pathogenesis.
The endothelium is a critical source of PDGF-B for
PDGF-β-positive mural cell recruitment, as demonstrated
by the endothelium-specific ablation of PDGF-B, which
leads to pericyte deficiency [117]. The blockade of pericyte
recruitment by abolishing PDGF-B/PDGFR-β signaling
causes a lack of basement membrane matrix deposition
and concomitantly increased vessel widths [118]. In
addition, the ectopic expression of PDGF-B by tumor cells
results in the increased recruitment of mural cells to
blood vessels on the establishment of subcutaneous tu-
mors [119,120]. Unfortunately, despite the tight physical
and functional association between ECs and pericytes,
there is a paucity of information about the signals ex-
changed between the two cell types in IHs. Reassuringly,
data from a separate study demonstrated that PDGF/
PDGF-R-β signaling may act as an intrinsic negative regu-
lator of IH involution. In this study, Roach and colleagues
[121] found that PDGF is elevated during the proliferating
phase and may inhibit adipocyte differentiation. The ex-
posure of HemSCs to exogenous PDGF results in an acti-
vation of autocrine PDGF/PDGF-R-β signaling, thereby
inhibiting IH involution. These findings highlight the in-
volvement of PDGF/PDGF-R-β signaling in the develop-
ment of IHs. Moreover, hemangioma-derived pericytes
also express PDGFR-β, although its effect has not been
elucidated in IH pathogenesis [42]. Thus, the possibility of
targeting HemSC and Hem-pericyte function, for ex-
ample, via their PDGF receptors, to gain enhanced efficacy
of antiangiogenic treatment regiments is supported by the
reports of beneficial effects of combining PDGFR inhibi-
tors with antiangiogenic drugs or regimens [118,122,123].
Conclusion and future challenges
In conclusion, the findings summarized above demon-
strate that signaling pathways involved in the development
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significant relevance to understanding IH pathogenesis.
However, similar to malignant tumors, there is extensive
crosstalk between individual signaling pathways in IH.
This crosstalk is generally due to two factors. First, mul-
tiple pathways often control a common process. Second,
many signaling outcomes impact other processes through
feedback loops and compensatory responses. Therefore,
elucidating the molecular pathogenesis of IH presents an
intriguing challenge. To solve this puzzle, an organized re-
construction of the sequential molecular perturbations
during IH neovascularization is required. Such an analysis
needs to combine data from different levels, including
genetic aberrations, expression alterations and protein
modification in a comprehensive set of tissue samples.
These issues should highlight the important role that the
increased knowledge of the molecular pathways involved
in the pathogenesis of IH will have in guiding the develop-
ment of effective, rationally designed therapeutic strat-
egies. Future research efforts will not only provide us with
a pharmacological basis of the therapeutic use of β-
blocker in IHs but also a basis for the further investigation
of other potential anti-hemangioma agents.
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